Dual mode for enhanced precision Dual mode for enhanced precision

Dual mode for
enhanced precision

Optimized results.
Minimal side effects.

Read more
Redefining non-thermal venous therapy Redefining non-thermal venous therapy

Redefining non-thermal
venous therapy

Optimized results.
Minimal side effects

Read more

VVT Medical (TSXv:VVTM) advances vein care with minimally invasive, office-based treatments that reduce procedural complexity, recovery time, and adverse effects.

Our proprietary products deliver precise, controlled therapy for patients with varying venous pathologies.

Smart Dual-mode solutions for various vein sizes

VVT’s product portfolio includes ScleroSafeTM and V-BlockTM, two synergistic, catheter-based solutions designed to treat the widest range of vein diameters in the market.
Leveraging a proprietary mechanochemical technology that combines controlled sclerosant injection and simultaneous vessel collapse and blood aspiration, our products deliver effective vein closure with minimal side effects.

In-office, short procedure

In-office,
short procedure

Precise, controlled treatment

Precise,
controlled treatment

Streamlined results

Streamlined
results

View products

VVT in the news

"The comparable closure rates and excellent safety profile indicate that ScleroSafe may deliver near‑thermal efficacy with nonthermal simplicity"

ScleroSafe Study Published in Indian Journal of Vascular and Endovascular Surgery (2026). New clinical data from Holy Spirit Hospital and Medical Research Centre in Mumbai was published in the Indian Journal of Vascular and Endovascular Surgery, highlighting the use of ScleroSafe in patients with symptomatic varicose veins. The study demonstrated strong early vein closure rates and an excellent safety profile, reinforcing its potential as an effective non-thermal approach in modern venous care.

Read more

VVT Medical received U.S. FDA clearance for its ScleroSafe™ platform.

This milestone marks a major regulatory achievement and formally establishes the pathway for the company’s entry into the U.S. market. The clearance enables VVT Medical to begin commercial activities in the United States, supporting broader adoption of its technology by physicians and advancing the company’s global growth strategy.

We attended the Expert Venous Management (EVM) 2025 Conference (May 30–31) at Englewood Hospital, New Jersey.

Led by Dr. Steve Elias with co-chairs Dr. Antonios Gasparis and Dr. Nicos Labropoulos, EVM stands out for its open, informal approach to real-world vein care. Live cases, candid discussions, and true cross-disciplinary exchange—less conference, more conversation.

VVT Medical has entered into a five-year distribution agreement with Medworks India for the commercialization of its ScleroSafe™ platform.

Under the agreement, Medworks - a leading healthcare distributor in India - will be responsible for the marketing, sales, and distribution of the ScleroSafe™ platform across the Indian market, leveraging its established network and deep expertise in advanced healthcare technologies.

We participated in the American Venous Forum (AVF) 2025 in Atlanta, one of the leading scientific meetings in venous and lymphatic disease.

The conference provided an important opportunity to engage with physicians, exchange clinical insights, and take part in discussions shaping the future of venous care, alongside vascular surgeons, interventional radiologists, and phlebologists from around the world.

New York, Northwell Health, Vascular & Endovascular Vein Care Center, and one of the largest healthcare systems in the U.S., has performed its first-ever ScleroSafe procedure.

“That was painless!” was the patient’s first reaction. Huge thanks to Dr. Antonios Gasparis, System Chief of Vein Disease and the entire Northwell team for their trust and professionalism.

TSXV Canada: Last week, we had the incredible honor of ringing the bell at the TSX Venture Exchange (TSXV), a milestone moment for VVT Medical! 

It marked the beginning of our next chapter as a publicly traded company and reinforced our commitment to advancing venous care through innovative, non-thermal, minimally invasive solutions.

Düsseldorf. Medica. We attended the Medica conference as part of the Israeli Pavilion.

We were honored to welcome Prof. Ralf Kolvenbach, esteemed vascular surgeon and distinguished member of the VVT Medical Advisory Board, to our booth. We met with numerous interested distributors, physicians, and potential partners who were fascinated by our technology.

Contact us

Contact Us

Section

Section

Consent